Royalty Depreciation And Amortization from 2010 to 2025

RPRX Stock  USD 33.64  0.27  0.81%   
Royalty Pharma Depreciation And Amortization yearly trend continues to be fairly stable with very little volatility. Depreciation And Amortization is likely to outpace its year average in 2025. Depreciation And Amortization is the systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives. View All Fundamentals
 
Depreciation And Amortization  
First Reported
2019-03-31
Previous Quarter
560 M
Current Value
137.8 M
Quarterly Volatility
187.8 M
 
Covid
Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 237.3 M, Total Revenue of 2.4 B or Research Development of 1.9 M, as well as many indicators such as Price To Sales Ratio of 4.79, Dividend Yield of 0.0362 or PTB Ratio of 1.05. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
  
Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Depreciation And Amortization Growth Pattern

Below is the plot of the Depreciation And Amortization of Royalty Pharma Plc over the last few years. It is the systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives. Royalty Pharma's Depreciation And Amortization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.
Depreciation And Amortization10 Years Trend
Slightly volatile
   Depreciation And Amortization   
       Timeline  

Royalty Depreciation And Amortization Regression Statistics

Arithmetic Mean105,743,012
Geometric Mean43,771,606
Coefficient Of Variation158.73
Mean Deviation126,175,394
Median33,267,000
Standard Deviation167,845,530
Sample Variance28172.1T
Range471.4M
R-Value0.65
Mean Square Error17264.8T
R-Squared0.43
Significance0.01
Slope23,064,784
Total Sum of Squares422581.8T

Royalty Depreciation And Amortization History

2025477.1 M
2024454.4 M
2023395.1 M
20225.7 M
202123 M
202023.1 M
201914.1 M

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Depreciation And Amortization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Depreciation And Amortization454.4 M477.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.